Last reviewed · How we verify
Abametapir Lotion 0.74% w/w
Abametapir is a topical pediculicide that inhibits lice metalloproteinases, disrupting their ability to feed and survive on the scalp.
Abametapir is a topical pediculicide that inhibits lice metalloproteinases, disrupting their ability to feed and survive on the scalp. Used for Head lice infestation (Pediculosis capitis).
At a glance
| Generic name | Abametapir Lotion 0.74% w/w |
|---|---|
| Also known as | Abametapir 0.74% |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | Metalloproteinase inhibitor (pediculicide) |
| Target | Lice metalloproteinases (zinc-dependent enzymes) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Abametapir works by blocking zinc-dependent metalloproteinases in head lice, which are essential enzymes the parasites use to penetrate skin and obtain blood meals. By inhibiting these enzymes, the drug prevents lice from feeding and reproducing, leading to their death. This novel mechanism of action differs from traditional neurotoxic pediculicides, potentially offering advantages in resistance management.
Approved indications
- Head lice infestation (Pediculosis capitis)
Common side effects
- Application site erythema
- Application site irritation
- Scalp irritation
Key clinical trials
- Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion (PHASE1)
- Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation (PHASE2)
- A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation (PHASE3)
- Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation (PHASE3)
- Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abametapir Lotion 0.74% w/w CI brief — competitive landscape report
- Abametapir Lotion 0.74% w/w updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI